Literature DB >> 11028841

In vitro migration of mononuclear cells towards synovial fluid and plasma from rheumatoid arthritis patients correlates to RANTES synovial fluid levels and to clinical pain parameters.

T Ellingsen1, A Buus, B K Møller, K Stengaard-Pedersen.   

Abstract

OBJECTIVE: To evaluate in vitro migration of mononuclear cells towards synovial fluid (SF) and plasma in relation to RANTES synovial fluid levels and clinical disease activity.
METHODS: 31 RA patients with synovitis in one knee were included. Modified Boyden chamber technique was used to determine a migratory index defined as: 'In vitro migrating cells towards SF' divided by 'In vitro migrating cells towards plasma'. RANTES was quantified by ELISA. Disease activity was assessed by the swollen joint count, the Ritchie articular index (RAI), global assessment, pain on VAS, HAQ, ESR and CRP.
RESULTS: A positive significant correlation was found between the migratory index and the RANTES levels in SF (r=0.48, p=0.006), the RAI (r=0.56, p=0.0001) and pain on VAS (r=0.43, p=0.04). The in vitro migration could be inhibited in 3 of 4 SF samples by neutralising antibodies towards RANTES (12-18%).
CONCLUSION: The migratory index correlate to SF levels of RANTES and parameters for joint pain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028841     DOI: 10.1080/030097400750041343

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

1.  Serum chemokines in patients with rheumatoid arthritis treated with etanercept.

Authors:  Piotr Adrian Klimiuk; Stanislaw Sierakowski; Izabela Domyslawska; Justyna Chwiecko
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

2.  RANTES deficiency attenuates autoantibody-induced glomerulonephritis.

Authors:  Chun Xie; Kui Liu; Yuyang Fu; Xiangmei Qin; Geetha Jonnala; Tao Wang; Hong W Wang; Michael Maldonado; Xin J Zhou; Chandra Mohan
Journal:  J Clin Immunol       Date:  2010-10-01       Impact factor: 8.317

3.  Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.

Authors:  Alan T Clucas; Ajit Shah; Yuanchao Derek Zhang; Vincent F Chow; Ronald P Gladue
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis.

Authors:  Piotr Adrian Klimiuk; Jacek Kita; Justyna Chwiecko; Stanislaw Sierakowski
Journal:  Clin Rheumatol       Date:  2008-07-29       Impact factor: 2.980

5.  The effect of infliximab on chemokines in patients with rheumatoid arthritis.

Authors:  Eiji Torikai; Yasunori Kageyama; Motohiro Suzuki; Tetsuya Ichikawa; Akira Nagano
Journal:  Clin Rheumatol       Date:  2006-11-17       Impact factor: 3.650

6.  RANTES and chemotactic activity in synovial fluids from patients with rheumatoid arthritis and osteoarthritis.

Authors:  Joanna Stanczyk; Marek L Kowalski; Janina Grzegorczyk; Barbara Szkudlinska; Marzanna Jarzebska; Marek Marciniak; Marek Synder
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

7.  Chemokine Receptor 5 Antagonism Causes Reduction in Joint Inflammation in a Collagen-Induced Arthritis Mouse Model.

Authors:  Mushtaq A Ansari; Ahmed Nadeem; Saleh A Bakheet; Sabry M Attia; Mudassar Shahid; Faris S Alyousef; Mohammed A Alswailem; Mohammed Alqinyah; Sheikh F Ahmad
Journal:  Molecules       Date:  2021-03-25       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.